Wave Life Sciences, Inc. (WVE)
$5.13-$0.03 (-0.58%) Today
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
https://www.wavelifesciences.comSEC filings for WVE on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 4 | 23,996 | $135K |
| Option exercise | 2 | 14,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
42 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Ordinary Shares | 12,700 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Share Option (Right to Buy) | 76,200 | $0.00 | - | |
| Christian O. Henry | Grant or award | Ordinary Shares | 12,700 | $0.00 | - | |
| Christian O. Henry | Open-market sale | Ordinary Shares | 9,670 | $8.81 | $85K | |
| Christian O. Henry | Grant or award | Share Option (right to buy) | 76,200 | $0.00 | - | |
| Aik Na Tan | Grant or award | Ordinary Shares | 25,400 | $0.00 | - | |
| Aik Na Tan | Grant or award | Share Option (right to buy) | 152,400 | $0.00 | - | |
| Ken Takanashi | Open-market sale | Ordinary Shares | 4,872 | $8.75 | $43K | |
| Aik Na Tan | Open-market sale | Ordinary Shares | 1,127 | $8.75 | $10K | |
| Paul Bolno - Officer | Option exercise | Ordinary Shares | 50,000 | $2.48 | $124K | |
| Paul Bolno - Officer | Open-market sale | Ordinary Shares | 50,000 | $15.00 | $750K | |
| Paul Bolno - Officer | Option exercise | Share Option (right to buy) | 50,000 | $0.00 | - | |
| Paul Bolno - Officer | Open-market sale | Ordinary Shares | 51,234 | $14.32 | $734K | |
| Chris Francis - Officer | Option exercise | Ordinary Shares | 36,000 | $8.17 | $294K | |
| Chris Francis - Officer | Open-market sale | Ordinary Shares | 36,000 | $16.00 | $576K | |
| Chris Francis - Officer | Option exercise | Share Option (right to buy) | 36,000 | $0.00 | - | |
| Chris Francis - Officer | Open-market sale | Ordinary Shares | 79,714 | $14.00 | $1.12M | |
| Chris Francis - Officer | Option exercise | Ordinary Shares | 40,997 | $2.48 | $102K | |
| Chris Francis - Officer | Open-market sale | Ordinary Shares | 40,997 | $13.00 | $533K | |
| Chris Francis - Officer | Option exercise | Ordinary Shares | 65,625 | $3.14 | $206K | |
| Chris Francis - Officer | Open-market sale | Ordinary Shares | 65,625 | $13.75 | $902K | |
| Chris Francis - Officer | Option exercise | Ordinary Shares | 22,500 | $2.83 | $64K | |
| Chris Francis - Officer | Open-market sale | Ordinary Shares | 22,500 | $13.50 | $304K | |
| Chris Francis - Officer | Option exercise | Share Option (right to buy) | 40,997 | $0.00 | - | |
| Chris Francis - Officer | Option exercise | Share Option (right to buy) | 65,625 | $0.00 | - | |
| Chris Francis - Officer | Option exercise | Share Option (right to buy) | 22,500 | $0.00 | - | |
| Paul Bolno - Officer | Open-market sale | Ordinary Shares | 90,474 | $15.00 | $1.36M | |
| Kyle Moran - Officer | Option exercise | Ordinary Shares | 25,000 | $2.48 | $62K | |
| Kyle Moran - Officer | Option exercise | Share Option (right to buy) | 25,000 | $0.00 | - | |
| GSK plc - 10% Owner | Open-market purchase | Ordinary Shares | 2,791,930 | $8.00 | $22.34M |
This is as far as the anonymous view goes. Create a free account for all 42 WVE filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| ADRIAN G RAWCLIFFE | Director | 12,700 | $64K | View on EDGAR | |
| HEIDI L WAGNER | Director | 7,000 | $42K | View on EDGAR |
Wave Life Sciences, Inc. (WVE) had 4 insider filings in the last 90 days, with the most recent on 2026-08-14. The full record for WVE runs to 42 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of WVE were filed in the last 90 days. 6 purchases are on record for this company.
4 insider sales of WVE were filed in the last 90 days, totaling $135K.
This page tracks WVE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add WVE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
